Table 3.

Summary of Histone Modifications in Bloodstream Forms

Histone	N-terminus	Acetyl Lysine	Methyl Lysine
H2A	A1_me1 (60%)^a,^b	K4 (1%)^a	none
	A1_ac^a	K115^b
		K119^b
		K120^b
		K122^b
		K125^b
		K128^b
H2B	A1_me1 (60%)^a,^b	K4 (1%)^a	none
	A1_me2^b	K12^b
		K16^b
H3	S1_ac^b	K23^b	K32_me3^b
			K76_me1, K76_me2, K76_me3^b
H4	A1_me1 (60%)^a,^b	K2 (2%)^a,^b	K2_me2^b
		K4 (73%)^a,^b	K17_me1 (4%), K17_me2 (8%), K17_me3 (9%)^a,^b
		K5 (7%)^a,^b
		K10 (7%)^a,^b	K18_me1 (6%), K18_me2 (4%), K18_me3 (18%)^a,^b
		K14 (1%)^a

PTMs observed by Edman degradation. The levels of acetylation and methylation, shown in parenthesis, were quantified by comparison to known standards.

PTMs observed by tandem MS

K_me1, K_me2, and K_me3 refer to mono-, di-, and tri-methyl lysine, respectively; A_ac, A_me1, and A_me2 refer to acetyl, monomethyl, and dimethyl alanine, respectively; S_ac refers to acetyl serine.